iGMDRD276


Canonical SMILES: C1=CC2=NC=CN=C2C=C1C=C3C(=O)NC(=O)S3

InChI: InChI=1S/C12H7N3O2S/c16-11-10(18-12(17)15-11)6-7-1-2-8-9(5-7)14-4-3-13-8/h1-6H,(H,15,16,17)/b10-6-

InChI Key: SQWZFLMPDUSYGV-POHAHGRESA-N

Loading, please wait...
Standard Name
CHEMBL
Pubchem CID
DRUGBANK ID
Drug Status
Drug Type
Standard NameAS 605240
Pubchem CID5289250
DRUGBANK IDDB04769
Drug StatusAlone
Drug TypeSmall Molecule

Drug Targets:

PIK3CG (P48736)

Drug Pathways:

PI3K/MTOR signaling

Drug-model tissue-cancer distribution: Bubble Plot

BREAStissue: BREAS cancer: BREAST model num: 0BREASTtissue: BREAST cancer: Breast Carcinoma model num: 1undefinetissue: undefine cancer: undefined model num: 0undefinedtissue: undefined cancer: PANCAN model num: 1BOWEtissue: BOWE cancer: BOWEL model num: 0BOWELtissue: BOWEL cancer: Colorectal Adenocarcinoma (COADREAD) model num: 1BONtissue: BON cancer: BONE model num: 0BONEtissue: BONE cancer: Acute Myeloid Leukemia (AML) model num: 1LUNtissue: LUN cancer: LUNG model num: 0LUNGtissue: LUNG cancer: Lung Adenocarcinoma (LUAD) model num: 1PANCREAtissue: PANCREA cancer: PANCREAS model num: 0PANCREAStissue: PANCREAS cancer: Pancreatic Adenocarcinoma (PAAD) model num: 1SKItissue: SKI cancer: SKIN model num: 0SKINtissue: SKIN cancer: Cutaneous Melanoma (SKCM) model num: 1

Drug-gene pathway enrichments

Drug-gene GO enrichments

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
3845 KRAS 1
659 BMPR2 1
7157 TP53 1
4089 SMAD4 2
Showing 1 to 4 of 10 rows

Gene in drug-gene network: Network Plot

selumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorsCompound 44Compound 44MEK inhibitorsMEK inhibitorscetuximabcetuximabCobimetinibCobimetinibSorafenibSorafenibPanitumumabPanitumumabBRAF inhibitorsBRAF inhibitorspan-RAF inhibitorspan-RAF inhibitorsPLX-4720PLX-4720DabrafenibDabrafenibVemurafenibVemurafenibRefametinibRefametinibTrametinibTrametinibBRAFBRAFBMS-754807BMS-754807salermidesalermideBIX01294BIX01294Nutlin-3aNutlin-3aMytomycin CMytomycin CY-39983Y-39983NSC141540NSC141540Liposomal DoxorubicinLiposomal DoxorubicinGemcitabineGemcitabineCis-PlatinCis-PlatinindisulamindisulamTP53TP53MST-312MST-312RITARITABMS-536924BMS-536924PD-0332991PD-0332991TamoxifenTamoxifenitraconazoleitraconazoleCompound.7d.cisCompound.7d.cisCamptothecinCamptothecinABT-751ABT-751pifithrin-mupifithrin-mupenfluridolpenfluridolAM-580AM-580VX-680VX-680TW-37TW-37OSU-03012OSU-03012179324-69-7179324-69-7RO-3306RO-3306SDHCSDHCPP-30PP-30kinetin ribosidekinetin ribosideGefitnibGefitnibCHEMBL399379CHEMBL399379ErlotinibErlotinibPD0325901PD0325901PI3K pathway inhibitorsPI3K pathway inhibitorsSarcolysinSarcolysinRegorafenibRegorafenibKRASKRASCDK4/6 inhibitorsCDK4/6 inhibitorscytochalasin.Bcytochalasin.BVER 155008VER 155008BI-2536BI-2536ubistatin Bubistatin BABT737ABT737FedratinibFedratinibChloropentafluorobenzeneChloropentafluorobenzeneBinimetinib (MEK162)Binimetinib (MEK162)NRASNRASPI3K pathway inhibitors (alone or in combination)PI3K pathway inhibitors (alone or in combination)quinoclaminequinoclamineEverolimusEverolimusisoevodiamineisoevodiamineparbendazoleparbendazoletosedostattosedostatoligomycin.Aoligomycin.AML214ML214triptolidetriptolideBRD7137BRD7137BYL719 (Alpelisib)BYL719 (Alpelisib)trastuzumab alonetrastuzumab alonePIK3CAPIK3CABRD63610BRD63610Merck60Merck60TGX-115TGX-115SirolimusSirolimusTET2TET2tipifarnib-P2tipifarnib-P2IdarubicinIdarubicinParthenolideParthenolidenakiterpiosinnakiterpiosinleucascandrolide Aleucascandrolide ApiperlonguminepiperlongumineBRD9876BRD9876pevonedistatpevonedistatCD437CD437MECOMMECOMELCPKELCPKnavitoclaxnavitoclaxISX-9ISX-9GW-843682XGW-843682XAfatnibAfatnibYK.4.279YK.4.279SepantroniumSepantroniumBRD4354BRD43543-chloro-L-alanine3-chloro-L-alanineteniposideteniposideLexibulinLexibulin4-methylfasudil4-methylfasudilCHM-1CHM-1SMAD4SMAD4CAY10618CAY10618FK 866FK 866PNU-74654PNU-74654bistramide Abistramide AGMX1778GMX1778JQ1 CompoundJQ1 CompoundPemetrexedPemetrexedBMPR2BMPR2AS 605240AS 605240

Models in AS 605240

Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
AMP(SDHC) gene GDSC BREAST Breast Carcinoma AS605240 sensitivity in vitro
MUT(BRAF)|MUT(NRAS)|PWU(JAK-STAT) mix GDSC undefined PANCAN AS605240 sensitivity in vitro
¬MUT(BMPR2)&DEL(MUT(SMAD4))|¬MUT(PIK3CA)&MUT(SMAD4) mix GDSC BOWEL Colorectal Adenocarcinoma (COADREAD) AS605240 sensitivity in vitro
MUT(TET2) mix GDSC BONE Acute Myeloid Leukemia (AML) AS605240 sensitivity in vitro
DEL(17p11.2)|AMP(MECOM) mix GDSC LUNG Lung Adenocarcinoma (LUAD) AS605240 sensitivity in vitro
¬MUT(SMAD4)&(KRAS)&¬PWU(MAPK_PI3K) mix GDSC PANCREAS Pancreatic Adenocarcinoma (PAAD) AS605240 sensitivity in vitro
¬MUT(TP53)&¬DEL(16q23.1)&¬AMP(FOXP1,MITF)&¬PWD(Wnt) mix GDSC SKIN Cutaneous Melanoma (SKCM) AS605240 sensitivity in vitro
Showing 1 to 7 of 7 rows

​​​​